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ABSTRACT
Objectives There is growing recognition around the 
importance of multimorbidity in low- income and middle- 
income country (LMIC) settings, and specifically the 
need for pragmatic intervention studies to reduce the 
risk of developing multimorbidity, and of mitigating the 
complications and progression of multimorbidity in LMICs. 
One of many challenges in completing such research has 
been the selection of appropriate outcomes measures. A 
2018 Delphi exercise to develop a core- outcome set for 
multimorbidity research did not specifically address the 
challenges of multimorbidity in LMICs where the global 
burden is greatest, patterns of disease often differ and 
health systems are frequently fragmented. We, therefore, 
aimed to summarise and critically review outcome 
measures suitable for studies investigating mitigation of 
multimorbidity in LMIC settings.
Setting LMIC.
Participants People with multimorbidity.
Outcome measures Identification of all outcome 
measures.
Results We present a critical review of outcome 
measures across eight domains: mortality, quality of 
life, function, health economics, healthcare access and 
utilisation, treatment burden, measures of ‘Healthy Living’ 
and self- efficacy and social functioning.
Conclusions Studies in multimorbidity are necessarily 
diverse and thus different outcome measures will be 
appropriate for different study designs. Presenting the 
diversity of outcome measures across domains should 
provide a useful summary for researchers, encourage the 
use of multiple domains in multimorbidity research, and 
provoke debate and progress in the field.
INTRODUCTION
There is growing recognition around the 
importance of multimorbidity in low- income 
and middle- income countries (LMICs).1 
Multimorbidity, as defined by the UK 
Academy of Medical Sciences (AMS), refers 
to ‘the coexistence of two or more chronic 
conditions, each of which is either a phys-
ical non- communicable disease (NCD) of 
long duration, a mental health condition 
of long duration or an infectious disease of 
long duration’.1 The AMS report highlights 
the challenges in delivering multimorbidity 
research,2 including the selection of appro-
priate outcome measures. In 2018, Smith 
completed a Delphi exercise to develop 
a core- outcomes set for multimorbidity 
research (COSmm).3 The highest scoring 
outcomes were health- related quality of life, 
mental health outcomes and mortality. While 
ground- breaking, this process did not specif-
ically target the challenges of multimorbidity 
in LMICs where the global burden is greatest, 
patterns of disease often differ and health 
systems are frequently fragmented.
Strengths and limitations of this study
 ► There is no existing review of outcome measures 
suitable for use in studies to mitigate multimorbidity 
in low- income and middle- income country (LMIC) 
settings.
 ► The article is the written by the Global Alliance for 
Chronic Diseases researchers.
 ► It is not a systematic review.
 ► Further work is required to develop a core- outcome 
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The Global Alliance for Chronic Diseases (GACD) is an 
alliance of health research funders, whose research teams 
form a network of multidisciplinary researchers from 
both LMICs and high- income countries (HICs). We aim 
to reduce the impact of NCDs through a focus on imple-
mentation science research in LMICs, and high- priority 
populations in HICs. Recognising synergies across our 
disease- specific programmes, in 2017, we formed a 
Multimorbidity Working Group and published a GACD 
Researchers’ Statement concluding that ‘a greater focus 
on multimorbidity is overdue and necessary to success-
fully improve global health outcomes’, thus acknowl-
edging the specific challenge of multimorbidity in the 
LMIC context.4 The statement went on to propose three 
strategic objectives, one of which was to change the way 
research is commissioned, funded and delivered when 
considering NCDs in LMICs.
Discussion with research funders subsequently high-
lighted that one barrier to funding research addressing 
multimorbidity in LMICs was a perceived lack of robust 
outcome measures. We have, therefore, developed this 
GACD Researchers’ perspective on outcome measures 
suitable for studies of multimorbidity in LMICs, taking 
into account the challenges of (routine) data collection 
and patient–provider factors such as differences in inter-
preting social constructs and health literacy. The intent is 
to build on the COSmm work.3 Derived from a common 
base of expertise in NCD implementation research in 
LMICs, we present a diversity of potential measures that 
can accommodate different aspects of impact in LMICs, 
ranging from individual- level outcomes to health service 
and health system effects. This is not an attempt to 
provide a core outcome measures set. Rather, together, 
the potential outcome measures inform different evalua-
tions of effectiveness and/or process for multimorbidity. 
We present these as a useful resource for those designing 
and reviewing intervention studies for multimorbidity 
in LMIC settings, and hope this initiative may promote 
harmonisation across studies that will be essential to better 
map the impact of multimorbidity in LMIC settings.
METHOD
Potential outcome measures suitable for studies of multi-
morbidity in LMICs were collected through a survey among 
the GACD multimorbidity working group, and distilled 
by the writing committee (the Authors) into categories 
through consensus discussion. All GACD researchers were 
invited to take part in the multimorbidity working group 
and those expressing interest were then invited to provide 
suggestions for suitable outcome measures via free- text 
e- mail to the group leads. In total, 31 group members 
participated (listed as the Authors and Contributors), 
with representation from all WHO Regions except the 
Eastern Mediterranean. GACD researchers have consid-
erable collective experience conducting implementation 
science trials in LMIC settings. All measures had to be 
suitable for use in multimorbidity intervention studies in 
LMIC, either at the individual or the population level, and 
from an implementation science perspective. Criteria for 
suitability included ease of measurement (such as avail-
ability of data, ease of data collection, availability of local 
translations and cost), generalisability (applicability of 
the proposed outcome across diverse populations within 
and between LMIC settings) and statistical considerations 
(the feasibility of demonstrating a clinically significant 
change with conventional statistical significance). Each 
outcome approach is fully described below. The initial 
synthesis was reviewed by members of the GACD Multi-
morbidity Working Group for additional comments and 
suggestions (the Contributors). The resulting narrative 
review summarises the group’s collective thoughts within 
each domain of outcome measures studied.
Patient and public involvement
Patients or the public were not involved in the design, 
conduct, reporting or dissemination plans of our research.
OUTCOME MEASURES FOR MULTIMORBIDITY INTERVENTIONS 
IN LMIC
Mortality
Death is the final common outcome for all individuals. 
Thus (premature) mortality is the most broadly appli-
cable, generalisable and comparable outcome for multi-
morbidity research. Indeed, mortality was considered as 
an ‘essential’ core outcome measure for multimorbidity 
research according to the COSmm consensus.3
However, precisely because mortality is so broadly 
applicable, it suffers from a lack of specificity. While 
cause- specific mortality is a potential solution to the issue 
of specificity, this approach moves away from the goal of 
multimorbidity- based outcome consideration. In addi-
tion, mortality does not reflect the quality of life that 
an individual experiences during the time of survival; 
particularly in the context of multimorbidity, both 
disability and quality of life considerations are important 
in terms of an individual’s experience of illness, wellness 
and life. Indeed, death is not always the most important 
outcome from a patient- centred perspective, as has been 
demonstrated in studies assessing patient preferences of 
different potential health outcomes5–7 and conceptual-
ised as disability- adjusted life years.
Practical challenges with mortality as an outcome 
measure include statistical power and sample size for 
an outcome that is relatively rare compared with other 
outcomes and proxies, potentially requiring much longer 
follow- up periods, except for older and/or more severely 
affected populations. It is, however, generally easy to 
measure and while the primary cause may be ascer-
tained through techniques such as verbal autopsy (2016 
WHO VA standard),8 assessing the contribution of multi-
morbidity at verbal autopsy is more challenging. While 
misclassifying the cause of death can impact the effect 
size for cause- specific mortality, power will be preserved 
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deaths remains difficult due to the lack of mature vital 
registry systems and cultural traditions promoting deaths 
at home with delay in reporting.
Thus, mortality as an outcome for multimorbidity 
research has been infrequently used, particularly in the 
context of LMIC settings.9–11 Demographic surveillance 
sites that have a long record of verbal autopsy could, 
however, provide a useful data reservoir to examine asso-
ciations between multimorbidity and mortality.
Generic quality of life scales
Health- related quality of life (HRQoL) instruments 
measure multidimensional well- being and functioning. 
Such scales may be generic such as EQ- 5D and 36- item 
Short Form Survey (SF-36), or disease (/area) specific. 
While disease- specific measures may have better content 
and face validity as well as better responsiveness and sensi-
tivity to change compared with generic measures, generic 
measures are (by definition) not disease specific and 
likely better for comparison of HRQoL among different 
diseases and for diseases in combination, an important 
consideration for multimorbidity research. Tools to assess 
the related construct of self- reported well- being have 
been reviewed and summarised elsewhere.12
Among generic tools, the COSmm consensus3 ranked 
the EQ- 5D, SF-36 and 12- item Short Form Survey (SF-12), 
and Global quality of life (WHOQOL- BREF) most highly.
The EQ- 5D13 has been widely used since introduction 
in the 1990s, facilitating health economic analysis (see 
below). It is designed to be completed by the participant 
and is available in multiple languages and thus widely 
applicable. The EQ- 5D questionnaire has two compo-
nents (health state description and evaluation). In the 
health state description, health status is measured across 
five dimensions: mobility, self- care, usual activities, pain/
discomfort and anxiety/depression. In the evaluation 
section, the respondents evaluate their overall health 
status using a Visual Analogue Scale.
The SF-3614 has 36 questions across eight domains: 
vitality, physical functioning, bodily pain, general health 
perceptions, physical role functioning, emotional role 
functioning, social role functioning and mental health.
The WHOQOL- BREF15 is an abbreviated version of the 
WHOQOL-100 quality of life assessment, originally devel-
oped by the WHOQOL Group working across fifteen 
international field centres to develop a quality of life 
assessment applicable across multiple settings.
HRQoL tools have a number of advantages over 
mortality as an outcome, being amenable to changes in 
the short term. HRQoL outcomes are particularly mean-
ingful as the aim of clinical treatment and management 
is generally optimising quality of life. Consequently, 
managing multimorbidity needs to take quality of life into 
account both as an outcome marker, but also an input 
factor into formulating clinical management. Practical 
considerations in LMIC include the availability of valid 
translations in local languages (these are more often 
available for the more commonly used tools, in the more 
commonly used languages, but coverage remains incom-
plete), and the challenges of use in populations with 
low literacy or understanding of Visual Analogue Scales. 
Other unanswered questions include whether thresholds 
for minimum clinically important difference (MCIDs) on 
these scales should be altered in the context of multimor-
bidity. Notably, some common NCDs such as hyperten-
sion are not generally associated with significant symptom 
burden.
Multidimensional indices of function
The AMS1 recommended that reports of multimorbidity 
should provide details of functional deficits or disabili-
ties and frailty. In both instances, the recommendation 
was made that this should be coded using a standardised 
classification scheme. For the former, the WHO Disability 
Assessment Schedule 2.0 (WHODAS 2.0) or the Interna-
tional Classification of Functioning, Disability and Health 
were suggested. For the latter, the cumulative deficit 
model of frailty or Fried’s phenotype model was recom-
mended (see below).
WHO Disability Assessment Schedule
The WHODAS 2.0 has been widely used in epidemio-
logical and observational studies in LMICs. It is a self- 
administered 12- item questionnaire that assesses six 
different adult life tasks over the preceding month. 
The specific areas covered are: (1) understanding and 
communication; (2) self- care; (3) mobility; (4) interper-
sonal relationships; (5) work and household roles and (6) 
community and civic roles. WHODAS has been included 
as a secondary outcome measure in three multimorbidity 
trials in LMIC (currently unreported16 17).
Frailty assessment instruments
There are many methods to assess frailty including the 
Fried Index, the Frailty Index and the British Frailty 
Index. While these have been used to examine the 
prevalence, correlates or outcomes of frailty in LMIC, 
further validation is still required in these settings.18 Of 
the various metrics, the Fried Index19 has been the most 
commonly used in LMIC. This index measures frailty by 
the presence of three or more of five physical deficits—
exhaustion, weakness, slowness, low levels of activity and 
weight loss. Three of the items are collected using ques-
tionnaires, but slowness is assessed using a walking test 
and weakness by assessing grip strength. The Frailty Index 
has also been commonly used in LMICs and uses the pres-
ence or absence of medical conditions or poor perfor-
mance on functional tasks to assess the number of deficits 
present and thus frailty.18 Using frailty as an outcome 
measure for intervention studies in patients with multi-
morbidity in LMIC may be limited by factors such as a 
lack of equipment (eg, to measure grip strength), and the 
question remains as to how susceptible to change such 
measurements are, and what an MCID might be. Despite 
this, frailty instruments remain an important outcome 
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factor in self- care, treatment adherence and family 
burden.
Assessment of physical functioning
Physical functioning measures are commonly studied 
outcomes. The most frequently used indices include 
activities of daily living (ADL) (such as eating, dressing 
and toileting), instrumental activities of daily living (such 
as shopping and answering phone calls) and the Barthel 
Index (self- reported outcomes on degree of assistance 
needed for mobility, self- care and continence). Smith et 
al3 described ADL, physical function and physical activity 
as core outcomes in multimorbidity interventions. For 
ADL the following measures received greatest support: 
Frenchay Activities Index, Nottingham Extended Activi-
ties of Daily Living and the Instructions for Activities of 
Daily Living questionnair, but these have not been evalu-
ated in the context of LMICs.
The modified Rankin Scale is an example of a disease- 
specific (in this case, stroke) composite outcome measure 
including rating of functioning from no interference 
with daily life, through various degrees of disability to 
death. These outcomes are relatively easy to assess and 
have particular relevance in LMICs as people generally 
express strong desires in maintaining physical func-
tioning including their ability to work, avoiding financial 
consequences and burden on family caregiving.
Health economic implications
The AMS report1 highlighted the economic burden of 
multimorbidity in LMICs and thus health economic 
implications are relevant in any consideration of multi-
morbidity outcome measures. However, most economic 
data on multimorbidity were gathered in HICs and the 
question arises as to whether measurement instruments, 
data and outcomes commonly used to assess cost implica-
tions of multimorbidity in HICs are applicable to LMIC 
settings.
One of the most common economic evaluations of 
healthcare interventions makes use of a technique called 
cost- effectiveness analysis and specifically the incremental 
cost- effectiveness ratio (ICER).20 The method to calculate 
the ICER is not disease specific, making it just as suitable 
to assess multimorbidity interventions as single disease 
interventions. However, it requires specific attention to 
the definitions and collection of costs and effect data in 
LMICs. Within this ratio, costs and effects can be defined, 
measured and calculated in different ways, of which some 
are more suitable in economic assessment of multimor-
bidity interventions in LMICs than others. Interpretation 
of the ratio may differ in different settings.
In healthcare, interventions can impact different types 
of direct and indirect costs within and outside health-
care systems. The different costs to be included in cost- 
effectiveness analysis depends on the perspective that is 
taken (eg, the healthcare payer, the society, the patient or 
the family). Costs that directly result from the interven-
tion and which occur within healthcare systems should 
be included when a healthcare payer perspective is taken. 
However, in LMICs that lack universal health coverage, 
the perspective of the patient and family may be more 
relevant and a key focus could be on out- of- pocket costs. 
Examples of indirect costs are work productivity losses 
and these costs are especially relevant when a patient or 
societal perspective is taken.
In health economic studies, the effect of intervention 
uses a measure that is independent of a specific disease: 
the quality- adjusted life year (QALY). The QALY is a 
combination of utility (preferably measured using the 
EQ- 5D) and survival. With the EQ- 5D, certain health 
states are defined, to which a specific utility is assigned. 
Utility is the value a society gives to a specified health state 
and for each country a specific algorithm should be esti-
mated from large general population samples. In many 
LMIC settings, these still need to be further developed to 
allow for generalisable models of effectiveness.
While most HICs have defined guidelines and make use 
of fixed thresholds or ranges to assess whether a certain 
ICER is considered cost- effective, such guidelines and 
thresholds are generally lacking in LMICs. This compli-
cates the interpretation of cost- effectiveness analyses in 
LMICs. As a general rule, WHO defines an intervention 
that costs less than three times the gross domestic product 
per capita as cost- effective.21 It is important to note that 
the implications of economic analyses discussed here are 
not challenges specific to multimorbidity, but are none-
theless suitable for the study of multimorbidity.
Healthcare access and utilisation
Multimorbidity is associated with repeated care seeking, 
often at different providers. This not only results in 
multiple interactions with healthcare settings through 
outpatient and inpatient admissions but also involves 
paramedical services and practitioners of traditional 
medicine.
Although we identified no study that has specifically 
looked at generating or testing multimorbidity related 
healthcare access indices in LMICs, the WHO Study on 
Global Ageing and Adult Health which focused on LMICs 
tracked indicators specific to multimorbidity in ageing 
populations.22 23 These included the number of outpa-
tient visits in the last 12 months, overnight hospital stays 
in the past 3 years, and the number of overnight stays in 
hospital in the past 12 months. A UK National Health 
Service document24 outlines equity indicators that may 
also map multimorbidity relevant in LMIC settings, and 
some of these have direct healthcare access relevance 
such as emergency hospitalisations for chronic condi-
tions and repeat emergency hospitalisations in the same 
year. Access to medicines listed on the WHO Essential 
Medications list would provide another metric, as would 
recommendations on attention to comorbidity and phar-
macological interactions in treatment guidelines.
This lack of LMIC specific multimorbidity indices 
to plot healthcare access leads to a critically important 
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in HICs.25 The latter work lists a range of objectives that 
need to be addressed in healthcare practices catering 
to clients with multimorbidity and lists a set of preven-
tive services for such cases which health facilities should 
provide. Health- seeking behaviour is a further dimen-
sion related to healthcare access that is shaped by unique 
socioeconomic and cultural contexts faced by patients in 
LMICs. We suggest it would be useful to develop health- 
seeking behaviour indices relevant across LMICs. This 
needs a contextual framework to best understand what 
is feasible and what can be tracked within specific LMIC 
settings, acknowledging the challenges introduced by the 
fragmentation of care and the multiplicity of levels of 
provision of care in the public and private sectors. Such 
indices could be linked with existing monitoring frame-
works used to assess Universal Health Coverage.26
The Global Burden of Disease initiative has recently 
incorporated a new metric at national level termed the 
Healthcare Access and Quality (HAQ) Index.27 The HAQ 
index is a scale from 0 to 100, calculated by measuring 
mortality rates from causes that should not be fatal 
(amenable mortality) in the presence of effective medical 
care. This correlates with the Sociodemographic Index, a 
measure of overall development consisting of income per 
capita, average years of education and total fertility rates.
Treatment burden
The burden of treatment, a relatively new concept, 
emerged from disease- centred healthcare systems in 
response to the growing needs of coping with chronic 
conditions. In the context of multimorbidity, this may be 
considered as the workload and impact on a patient as a 
result of receiving medical care.28 High treatment burden 
may lead to overwhelmed patients who struggle to access 
healthcare and adhere to suggested treatment while 
coordinating their own care and other aspects of life, a 
particular issue among patients with multimorbidity. As a 
consequence, polypharmacy and non- adherence to treat-
ment and poor clinical outcomes may follow, resulting in 
an even higher burden of treatment, a deterioration cycle 
depicted in the Cumulative Complexity Model.29 There-
fore, assessing treatment burden is a priority in order to 
achieve better quality healthcare, and treatment burden 
is a potential outcome measure in interventions directed 
against multimorbidity. There is also the challenge, more 
pronounced in LMICs, that in areas of no care there can 
be no ‘burden’ from treatment which it is impossible to 
access.
Assessing the burden of treatment is not an easy task. 
It generally requires multidimensional measures that are 
tailored to the medical condition(s), health system(s) 
and cultural background. Tailoring to specific conditions 
may diminish value in multimorbidity. Eton et al proposed 
a conceptual framework of treatment burden based on 
qualitative inquiries to patients with chronic conditions, 
consisting of 3 themes and 15 subthemes.30 A number 
of tools for evaluating treatment burden for patients 
with multimorbidity have been developed in the past 
few years. Eton et al designed and validated the Patient 
Experience with Treatment and Self- management.31 
The Treatment Burden Questionnaire (TBQ) is another 
instrument, consisting of 15 items32 and later further 
adapted.33 34 In 2018, Duncan published the Multimor-
bidity TBQ, a 10- item measure initially validated in 
primary care in the UK.35 The Healthcare Task Difficulty 
questionnaire is an 11- question tool designed to measure 
only one aspect—perceived difficulty in performing 
healthcare management tasks.36 Finally, the Multimor-
bidity Illness Perceptions Scale, unlike other instruments, 
was designed to measure the perceived impact of multi-
morbidity.37 The scale includes treatment burden (six 
questions) as one of the subscales.
As these questionnaires are relatively new, validation 
and translation for different populations and geograph-
ical areas remain limited, especially in LMICs. Exploring 
the notion and measurement of treatment burden in 
LMIC remains relatively unexplored,34 38 as does the 
important concept of patient- reported experience 
measures in LMIC settings which may themselves affect 
health outcomes.39
There are a number of remaining issues to be consid-
ered before applying these tools in LMICs. First, the 
strengths and limitations of each tool should be exam-
ined as careful validation has often not been conducted 
in such settings. Second, using mixed- methods incorpo-
rating experiences and opinions from patients and health-
care providers may help identify relevant issues relating 
to differences in contexts, cultures and health system 
structures. Third, as all of these instruments have been 
available for less than a decade, longitudinal evidence of 
change over time is absent.
Measures of ‘Healthy Living’
Multimorbidity is complex to operationalise, which 
makes common denominators very relevant. Measures 
of ‘Healthy Living’ are direct common denominators 
for being at risk of developing individual components 
of multimorbidity, and thus measuring change in these 
measures provides potential generic outcomes of inter-
ventions to mitigate future multimorbidity. Most current 
behavioural interventions have targeted only one 
behaviour at a time.
Healthy Living encompasses many different aspects of 
health and well- being, including diet, physical activity 
including sedentary behaviour, tobacco and alcohol 
consumption, developing health literacy, maintaining 
good hygiene and sanitation. Most current behavioural 
interventions have targeted only one behaviour at a time.
Diet
Dietary assessments are complex. Self- reported dietary 
intake measurements are the most common form of 
dietary assessments, which include prospective recording 
of actual food consumed or retrospective recall.40 41 With 
respect to multimorbidity, the focus must be on long- 
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measure that can be estimated for the individual, or the 
household using counts of food items (food variety score) 
or food groups (dietary diversity score) consumed over a 
prespecified period.42 43 Dietary diversity can be estimated 
at the Household level using the Household Dietary 
Diversity Score, which assesses household access to a 
variety of foods, or at individual level for women and chil-
dren respectively using the Minimum Dietary Diversity 
for Women of Reproductive Age tool and WHO Infant 
and Young Child Minimum Dietary Diversity Tool.44
Physical activity including sedentary behaviour
Convincing interventional evidence showing a clear 
dose–response relationship between physical activity 
(PA) and improved health outcomes comes mainly from 
HICs, although associations of PA with reduced cardio-
vascular mortality and morbidity are available globally.45 
Sedentary behaviour, defined as those that involve sitting 
or reclining and low levels of energy expenditure during 
waking hours,46 has also been associated with having at 
least two morbidities, independent of light, moderate or 
vigorous PA46 47 in HICs and LMICs. The Global Physical 
Activity Questionnaire (GPAQ) that is part of the WHO 
STEPwise Approach to Chronic Disease Risk Factor 
Surveillance data collection tool48 is a commonly used 
tool to collect self- reported data on PA. The GPAQ which 
is a shorter (16- item) version of the longer International 
Physical Activity Questionnaire also assesses sitting time in 
addition to PA in three domains (work, travel and leisure 
time). This is used to estimate the duration of moderate 
to vigorous PA or intensity in terms of metabolic equiva-
lent minutes per week of total and domain- specific activi-
ties. However, agreement between PA estimated by GPAQ 
and more objective measures has been moderate at best. 
Objective measures of PA allow real- time monitoring 
and can be easily completed using an application on a 
mobile device or a wearable pedometer or accelerom-
eter, although this has mostly been tested in HIC settings. 
Considering the rapid acceleration of smart phone 
ownership in LMIC, and the availability of cheaper but 
robust wearable devices, these are now viable options and 
an optional tool to capture objective PA has since been 
incorporated into the GPAQ.
Tobacco and alcohol use
Tobacco use has been consistently linked as a causative 
factor for chronic respiratory disorders such as chronic 
obstructive pulmonary disease, cardiovascular disease and 
many cancers including lung cancer. Similarly, alcohol 
use has strong associations with NCDs. Ever and current 
use of tobacco or current use of alcohol are commonly 
used assessments in addition to questions focusing on 
frequency and amount of consumption, and these are 
part of the WHO STEPS instrument.48 Where available, 
verification of smoking status can be achieved through 
measurement of carbon monoxide or urinary cotinine. 
Assessment of household, environmental and occupa-
tional airborne exposures are more complex.
Healthy Living Index
In addition to individual risks and behaviours, composite 
indicators that assess Healthy Living may be more rele-
vant in the context of multimorbidity. Tools to assess the 
environment in terms of its potential to offer opportu-
nities for Healthy Living have been limited, especially in 
LMICs. Environmental Profile of a Community’s Health 
(EPOCH) is a quantitative tool designed to capture 
community perceptions of tobacco, nutrition and social 
environments, validated in five countries (China, India, 
Brazil, Colombia and Canada).49 50 EPOCH comprises 
an objective assessment of the physical environment, 
and an interviewer- administered questionnaire on resi-
dents’ perceptions of their community to capture both 
objective and subjective measures of the environment.49 
The Community Healthy Living Index developed in the 
USA assessed the environmental support potential of a 
community across five domains assessing a specific venue: 
schools, afterschool child care sites, work sites, neigh-
bourhoods and communities- at- large.51 Such tools could 
be adapted for use in LMICs.
Self-efficacy and social functioning
Self- efficacy and social functioning relate to social deter-
minants of health such as age, gender, marital status, 
family background, employment, education level and 
socioeconomic status,52–58 affecting in turn how an indi-
vidual is able to look after their health conditions (self- 
efficacy) and interact in society with other individuals 
leading a fulfilling life (social functioning). This raises the 
important question of whether indices of self- efficacy and 
social functioning may be suitable as outcomes measures 
in studies to mitigate multimorbidity in LMIC settings.
There are limited studies that explore which social 
determinants are more influential than others in deter-
mining self- efficacy and social functioning. Positive 
personality traits and higher self- esteem demonstrated 
in adolescence positively affect self- efficacy.59 Compe-
tent behaviour, such as skills of focusing on others’ well- 
being, affiliative behaviours/interpersonal cooperation 
and participation, which are culturally valued and socially 
competent are associated with higher self- efficacy.60 61 
Liebke et al62 reported that loneliness and social func-
tioning are associated. Loneliness may be caused by 
impaired social skills, such as maintaining conversations 
or expressing feelings, which are essential to adequate 
social functioning.62 Values placed on social determinants 
of health may vary across different cultures. Differences 
in cultural traditions may affect the sources of self- efficacy 
belief systems.52 55 56
Given the multitude of cultural factors affecting the 
precursors of self- efficacy and social functioning, popula-
tions in LMICs may have fewer opportunities to develop 
such skills. Therefore, while measures of self- efficacy 
and social functioning could be used as multimorbidity 
outcome measure in LMIC, a single index is unlikely to 
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CONCLUSIONS
The case has been made for the growing global importance 
of multimorbidity, the need for pragmatic intervention 
studies to reduce the risk of developing multimorbidity in 
LMIC settings, and of mitigating the complications and 
progression of multimorbidity. One of many challenges 
in such research has been the selection of appropriate 
outcomes measures.
We present the GACD Researchers’ perspective on 
outcome measures suitable for multimorbidity interven-
tion studies in the context of LMICs. We have considered 
outcome measures across eight domains (figure 1). Some 
represent direct measurements of clinical outcomes, 
while others represent intermediate variables on the 
pathway to multimorbidity. Some measures are single, 
others are composite. They vary in their ease of collection 
and cost. It is critical to choose appropriate outcomes 
for the study design, cultural context and participant 
preference in order to demonstrate and understand the 
effect of an intervention, and our aim is therefore not to 
suggest a preference of one outcome measure over any 
other. Studies in multimorbidity are necessarily diverse 
and thus different outcome measures will be appro-
priate for different study designs. As with the COSmm 
consensus,3 we recognise the key importance of mortality 
and HRQoL as multimorbidity outcomes, and these are 
suitable for use in LMIC settings. Many other outcomes 
from the COSmm work, including patient- reported 
impacts and behaviours (such as treatment burden and 
self- efficacy), physical activity and function, and health 
systems indicators (notably health economic indices) are 
also suitable for LMIC settings, though in the context and 
with the caveats that we have described above. Some of 
the challenges applying these outcome measures in LMIC 
are also relevant in HIC.
The diversity of outcome measures across domains 
demonstrated here should provide a useful summary for 
researchers, and encourage the use of multiple domains 
in multimorbidity research, rather than just a single 
outcome measure. Ultimately, the proof of utility for 
these outcome measures will be the demonstration that 
an effective multimorbidity intervention can improve 
the health of the community in which it is tested. Mean-
while, there remains the urgent need for further study 
and development of outcome measures suitable for multi-
morbidity intervention studies in the context of LMIC.
There are limitations to this work, which is not intended 
to be a core outcome set, nor a systematic review. Devel-
opment of both these would be an important contribu-
tion to the field, as would further work to understand 
the perceptions of these outcome measures from people 
directly affected by multimorbidity and tools suitable 
for assessing patient- reported experience in the context 
of multimorbidity. Here, we present a critical, narrative 
synthesis describing the range of outcome measures that 
might be selected for use in such settings, and their chal-
lenges. The key strength of our work is the broad repre-
sentation of views from GACD researchers who have 
considerable collective experience of implementation 
science research in LMIC settings. We anticipate this will 
be useful to other researchers designing and conducting 
such studies, and to provoke debate and progress in the 
field.
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